Mitokinin
Dr. Muqit is a Programme Leader at the MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee. As one of the original discoverers of link between mutations in the PINK1 gene and Parkinson’s disease, he brings world-leading expertise in PINK1/Parkin pathway biology to the Mitokinin team as a member of the Scientific Advisory Board.
Miratul Muqit received his Ph.D from University College London under the supervision of Nick Wood and David Latchman. He undertook his neurology training at various London teaching hospitals including Queen Square. In 2008 he joined the MRC Protein Phosphorylation Unit in Dundee as a Wellcome Trust Intermediate Fellow to initiate a program of research into the biochemistry of the PINK1 kinase under the mentorship of Dario Alessi. Away from the bench he manages patients with Parkinson’s disease in the clinic.
This person is not in the org chart
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.